Top

International Ophthalmology

Published in:

01-11-2020 | Original Paper

Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series

Authors: Umut Dağ, Mehtap Çağlayan, Hasan Öncül, Mehmet Fuat Alakuş

Published in: International Ophthalmology | Issue 11/2020

Abstract

Purpose

To present 11 bodybuilding athletes who developed central serous chorioretinopathy (CSCR) following high-dose subcutaneous follistatin-344, a peptide-based performance and image enhancing drug, injections to increase muscle mass.

Methods

This is a retrospective case series from one institution. Demographic and clinical data of 11 patients who were admitted to our clinic with decreased visual acuity after high-dose follistatin-344 injections and optical coherence tomography (OCT) findings consistent with CSCR were analyzed.

Results

All 11 patients were male, and the mean age was 36.8 ± 8.1 years. All patients had a history of injecting complete 1 mg vials of follistatin-344 subcutaneously in the abdomen. There was a history of a single previous high-dose follistatin-344 injection in eight patients and multiple previous injections in three patients. At the time of diagnosis, ten patients had unilateral CSCR findings and one had bilateral CSCR findings. In all eight patients with a history of only one injection, subretinal fluid completely disappeared after an average of 2.3 ± 0.7 months and symptoms regressed. Recurrent CSCR developed in three patients with a history of multiple follistatin-344 injections.

Conclusion

Follistatin-344 injection can be considered as a risk factor for CSCR. To take medical history from CSCR patients including follistatin-344 use may be important to reveal the CSCR etiology.

Liew G, Quin G, Gillies M, Fraser-Bell S (2013) Central serous chorioretinopathy: a review of epidemiology and pathophysiology. Clin Exp Ophthalmol 41:201–214CrossRef

Nicholson BP, Atchison E, Idris AA, Bakri SJ (2018) Central serous chorioretinopathy and glucocorticoids: an update on evidence for association. Surv Ophthalmol 63:1–8CrossRef

Scarinci F, Ghiciuc CM, Patacchioli FR, Palmery M, Parravano M (2019) Investigating the hypothesis of stress system dysregulation as a risk factor for central serous chorioretinopathy: a literature mini-review. Curr Eye Res 44:583–589CrossRef

HaimoviciR KS, GagnonDR LT, Wellik S (2004) Central Serous chorioretinopathy case-control study group. risk factors for central serous chorioretinopathy: a case-control study. Ophthalmology 111:244–249CrossRef

Chatziralli I, Kabanarou SA, Parikakis E, Chatzirallis A, Xirou T, Mitropoulos P (2017) Risk factors for central serous chorioretinopathy: multivariate approach in a case-control study. Curr Eye Res 42:1069–1073CrossRef

Tittl MK, Spaide RF, Wong D et al (1999) Systemic findings associated with central serous chorioretinopathy. Am J Ophthalmol 128:63–68CrossRef

Daruich A, Matet A, Dirani A et al (2015) Central serous chorioretinopathy: recent findings and new physiopathology hypothesis. Prog Retin Eye Res 48:82–118CrossRef

Çiloğlu E, Unal F, Dogan NC (2018) The relationship between the central serous chorioretinopathy, choroidal thickness, and serum hormone levels. Graefes Arch Clin Exp Ophthalmol 256:1111–1116CrossRef

Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK, Mendell JR (2009) Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve 39:283–296CrossRef

10.

Kirk SE, Dalkin AC, Yasin M, Haisenleder DJ, Marshall JC (1994) GnRH puls frequency regulates expression of pituitary follistatin mRNA: a mechanism for differential gonadotrope function. Endocrinology 135:876–880CrossRef

11.

Phillips DJ, de Kretser DM (1998) Follistatin: a multifunctional regulatory protein. Front Neuroendocrinol 19:287–322CrossRef

12.

Patel K (1998) Follistatin. Int J Biochem Cell Biol 30:1087–1093CrossRef

13.

Grieshaber MC, Staub JJ, Flammer J (2007) The potential role of testosterone in central serous chorioretinopathy. Br J Ophthalmol 91:118–119CrossRef

14.

Wong SS, Morrison-Reyes JA, Smithen LM (2014) A case of central serous chorioretinopathy associated with use of deer antler spray supplement. Ophthalmic Surg Lasers Imaging Retina 45:256–258CrossRef

15.

Gass JD (1967) Pathogenesis of disciform detachment of the neuroepithelium II. Idiopathic central serous choroidopathy. Am J Ophthalmol 63:587–615

16.

Klein ML, Van Buskirk EM, Friedman E, Gragoudas E, Chandra S (1974) Experience with non-treatment of central serous choroidopathy. Arch Ophthalmol 91:247–250CrossRef

17.

Iida T, Hagimura N, Sato T, Kishi S (2000) Evaluation of central serous chorioretinopathy with optical coherence tomography. Am J Ophthalmol 129:16–20CrossRef

18.

McVeigh J, Kimergård A, Bates G, Hope VD, Ncube F (2016) Harm reduction interventions should encompass people who inject image and performance enhancing drugs. BMJ 353:1889CrossRef

19.

Corazza O, Bersani FS, Brunoro R, Valeriani G, Martinotti G, Schifano F (2014) The diffusion of performance and image-enhancing drugs (PIEDs) on the internet: the abuse of the cognitive enhancer piracetam. Subst Use Misuse 49:1849–1856CrossRef

20.

McVeigh J, Evans-Brown M, Bellis MA (2012) Human enhancement drugs and the pursuit of perfection. Adicciones 24:185–190CrossRef

21.

Barbé C, Bray F, Gueugneau M et al (2017) Comparative proteomic and transcriptomic analysis of follistatin-induced skeletal muscle hypertrophy. J Proteome Res 16:3477–3490CrossRef

22.

Sepulveda PV, Lamon S, Hagg A et al (2015) Evaluation of follistatin as a therapeutic in models of skeletal muscle atrophy associated with denervation and tenotomy. Sci Rep 5:17535CrossRef

23.

Conway MD, Noble JA, Peyman GA (2017) Central serous chorioretinopathy in postmenopausal women receiving exogenous testosterone. Retin Cases Brief Rep 11:95–99CrossRef

24.

Rocha EM, Wickham LA, da Silveira LA et al (2000) Identification of androgen receptor protein and 5alpha-reductase mRNA in human ocular tissues. Br J Ophthalmol 84:76–84CrossRef

25.

Spraul CW, Kaven C, Amann J, Lang GK, Lang GE (2000) Effect of insulin-like growth factors 1 and 2, and glucose on the migration and proliferation of bovine retinal pigment epithelial cells in vitro. Ophthalmic Res 32:244–248CrossRef

26.

Sakaue M, Hoffman BB (1991) Glucocorticoids induce transcription and expression of the 1β adrenergic receptor gene in DTTI MF-2 smooth muscle cells. J Clin Invest 88(385):389

27.

Miki T, Sunada I, Higaki T (1972) Studies on chorioretinitis induced in rabbits by stress (repeated administration of epinephrine). Nippon Ganka Gakkai Zasshi 76:1037–1045PubMed

28.

ValeW HA, Rivier C, Yu J (1990) The inhibin/activin family of growth factors. In: Sporn MA, Roberts AB (eds) Peptide growth factors and their receptors, handbook of experimental pharmacology. Springer, Heidelberg, pp 211–248CrossRef

29.

Bilezikjian LM, Blount AL, Campen CA, Gonzalez-Manchon C, Vale W (1991) Activin-A inhibits proopiomelanocortin messenger RNA accumulation and adrenocorticotropin secretion of AtT20 cells. Mol Endocrinol 5:1389–1395CrossRef

30.

Billestrup N, González-Manchón C, Potter E, Vale W (1990) Inhibition of somatotroph growth and growth hormone biosynthesis by activin in vitro. Mol Endocrinol 4:356–362CrossRef

31.

Nishi Y, Haji M, Tanaka S et al (1992) Human recombinant Activin-A modulates the steroidogenesis of cultured bovine adrenocortical cells. J Endocrinol 132:1–4CrossRef

32.

Schneyer AL, Wang Q, Sidis Y, Sluss PM (2004) Differential distribution of follistatin isoforms: application of a new FS315-specific immunoassay. J Clin Endocrinol Metab 89:5067–5075CrossRef

33.

Van Rijssen TJ, Van Dijk EHC, Yzer S et al (2019) Central serous chorioretinopathy: towards an evidence-based treatment guideline. Prog Retina Eye Res 73:100770CrossRef

34.

Haga F, Maruko R, Sato C, Kataoka K, Ito Y, Terasaki H (2017) Long-term prognostic factors of chronic central serous chorioretinopathy after half-dose photodynamic therapy: a 3-year follow-up study. PLoS ONE 12:e0181479CrossRef

35.

Loo RH, Scott IU, Jr Flynn HW et al (2002) Factors associated with reduced visual acuity during longterm follow-up of patients with idiopathic central serous chorioretinopathy. Retina 22:19–24CrossRef

36.

Torres-Soriano ME, Garcia-Aguirre G, Kon-Jara V et al (2008) A pilot study of intravitreal bevacizumab for the treatment of central serous chorioretinopathy (case reports). Graefes Arch Clin Exp Ophthalmol 246:1235–1239CrossRef

37.

Chan WM, Lai TY, Liu DT, Lam DS (2007) Intravitreal bevacizumab (avastin) for choroidal neovascularization secondary to central serous chorioretinopathy, secondary to punctate inner choroidopathy, or of idiopathic origin. Am J Ophthalmol 143:977–983CrossRef

38.

Chhablani J, Kozak I, Pichi F et al (2015) Outcomes of treatment of choroidal neovascularization associated with central serous chorioretinopathy with intravitreal antiangiogenic agents. Retina 35:2489–2497CrossRef

39.

Artunay O, Yuzbasioglu E, Rasier R, Sengul A, Bahcecioglu H (2010) Intravitreal bevacizumab in treatment of idiopathic persistent central serous chorioretinopathy: a prospective, controlled clinical study. Curr Eye Res 35:91–98CrossRef

40.

Kim M, Lee SC, Lee SJ (2013) Intravitreal ranibizumab for acute central serous chorioretinopathy. Ophthalmologica 229:152–157CrossRef

Title: Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series
Authors: Umut Dağ
Mehtap Çağlayan
Hasan Öncül
Mehmet Fuat Alakuş
Publication date: 01-11-2020
Publisher: Springer Netherlands
Published in: International Ophthalmology / Issue 11/2020
Print ISSN: 0165-5701
Electronic ISSN: 1573-2630
DOI: https://doi.org/10.1007/s10792-020-01501-6

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Central serous chorioretinopathy associated with high-dose follistatin-344: a retrospective case series

Abstract

Purpose

Methods

Results

Conclusion

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 11/2020

Rotational slit-beam marking: an advanced manual corneal astigmatic marking method for toric intraocular lens implantation

Relationship between vascular densities of choriocapillaris and the whole choroid using OCTA

Correction to: Visual, refractive and topographic outcomes of progressive thickness intrastromal corneal ring segments for keratoconic eyes

Current role of intravitreal injections in Irvine Gass syndrome-CRIIG study

Analysis of tear inflammatory molecules and clinical correlations in evaporative dry eye disease caused by meibomian gland dysfunction

Posterior uveal melanoma in 321 Asian Indian patients: analysis based on the 8th edition of American Joint Committee Cancer classification